How Often Do You See Neuroleptic Malignant Syndrome?
Question by Olga: How often do you see Neuroleptic Malignant Syndrome?
I’ve been working as a Psychiatric RN for a number of years now and I have never seen a single case of NMS.
How often do we still see NMS in current times?
Best answer:
Answer by rb43081
It is certainly believed that the risk/incidence of NMS (and all acute extrapyramidal syndromes) should be decreasing with the increased use of newer drugs. On the other hand, ALL drugs are being used more often, perhaps for longer periods of time and possibly, in patients of greater risk (older, for example).
Take a look at this:
Mov Disord. 2006 May;21(5):589-98.
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Tarsy D, Baldessarini RJ.
Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA. [email protected]
Abstract
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
=====================
Rex, a physician, in the midwest
Add your own answer in the comments!
Drug Treatment, Massachusetts – Stop Drug and Alcohol Abuse – SAVE a Loved One’s LIFE: 1-877-748-2833 **Phone Drug Rehab Intervention** Rehabilitation,Center,Addiction,New Jersey Drug Treatment, Massachusetts – Stop Dru…
GOP SPOTLIGHTS DOCTORS IN OBAMACARE WAR Ryans budget moment …
Filed under: drug treatment centers in massachusetts
Trey Radel completes his substance abuse treatment, abides by his supervised probation and returns to Congress next month, he still could face an ethics investigation. Congressional rules give the House Ethics Committee 30 days after a member has been …
Read more on Politico
MD Anderson Researchers Identify USP13 Enzyme for Vital Tumor-Suppressor
Filed under: drug treatment centers in massachusetts
A tumor-thwarting protein often missing in cancer cells (PTEN) has been discovered by researchers at The University of Texas MD Anderson Cancer Center and colleagues. According to senior author Li Ma, Ph.D., assistant professor of Experimental …
Read more on BioNews Texas
College Town
Filed under: drug treatment centers in massachusetts
Something contagious is spreading throughout Worcester-area juvenile correctional facilities run by the Massachusetts Department of Youth Services, and, two UMass Medical School students started it: Healthy habits. Last April, Julia Randall and Rahela …
Read more on Worcester Telegram